When was BioAtla founded?

BioAtla was founded in 2007 and raised its 1st funding round 7 years after it was founded.

Where is BioAtla located?

BioAtla is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does BioAtla have?

As of Feb 28, 2026, the latest employee count at BioAtla is 52.

Is BioAtla a funded company?

BioAtla is a funded company, having raised a total of $162M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 11, 2014.

When was the latest funding round of BioAtla?

BioAtla's latest funding was a $***** Series D round on Jul 15, 2020, with participation from 7 investors.

Where does BioAtla rank among its competitors?

BioAtla ranks 160th amongst 3495 active competitors, of which 1190 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of BioAtla?

BioAtla's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

BioAtla - 2026 Company Profile, Funding, Competitors & Financials

BioAtla is a public company based in San Diego (United States), founded in 2007. It operates as a Developer of immunotherapies for cancer using active biologics platform. BioAtla has raised $162M in funding from HBM Healthcare Investments and Soleus Capital. The company has 3495 active competitors, including 1190 funded and 813 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immunotherapies for cancer using active biologics platform. The platform technology is known as Conditionally Active Biologics (CABs). CAB-designed monoclonal antibodies selectively bind their antigen in the context of diseased tissue by exploiting the unique microenvironment of diseased vs normal tissue. Its pipeline includes antibodies for cancer, hematological cancer, and autoimmune disease.

Website: bioatla.com
Registered Address: San Diego, California

Key Metrics

Founded Year

2007

Location

San Diego, United States

Stage

Public

Total Funding

$162M in 5 rounds

Latest Funding Round

Series D, Jul 15, 2020, $*****

Investors

HBM Healthcare Investments & 16 more

Ranked

160^th among 3495 active competitors

Employee Count

52 as on Feb 28, 2026

Similar Companies

Jazz Pharmaceuticals & 3281 more

Exit Details

Public

View BioAtla's full profile

BioAtla is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bioatla, Inc. CIN: 1826892 , United States, Active	Mar 14, 2019	-	-	-
Bioatla Llc CIN: 208760096 , United States, Active	Dec 31, 2006	-	77 (As on Dec 31, 2024)	-

BioAtla got listed on Dec 16, 2020.

Click here to take a look at BioAtla's IPO in detail

BioAtla has raised a total funding of $162M over 5 rounds. Its first funding round was on Apr 11, 2014. Its latest funding round was a Series D round on Jul 15, 2020 for $*****. 7 investors participated in its latest round. BioAtla has 17 institutional investors.

Here is the list of recent funding rounds of BioAtla:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2020	2756187	Series D	2356603	5638041	7369393	8158292
Apr 01, 2016	8871944	Grant (prize money)	8303823	4886871	4887863	HHS
Jan 11, 2016	8550458	Series B	1950937	2113806	5310635	8908231

Access funding benchmarks and valuations. Sign up today!

View details of BioAtla's funding rounds and investors

BioAtla's employee count trend

BioAtla has 52 employees as of Feb 26. Here is BioAtla's employee count trend over the years:

Uncover BioAtla's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioAtla include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of BioAtla, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
160th	BioAtla 2007, San Diego (United States), Public	Developer of immunotherapies for cancer using active biologics platform	$162M	HTIF, Boxer Capital & 15 others	61/100